Phase 2 N=22 Randomized Triple-blind Treatment

Clonidine Versus Adenosine to Treat Neuropathic Pain

Pain

Bottom Line

View on ClinicalTrials.gov: NCT00349921 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2014

Primary outcome: Primary: Number Meeting Success Criterion — 10; 5; 0 participants meeting success criterion — p=>0.05

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: clonidine (Drug); adenosine (Drug); placebo (Drug)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Wake Forest University Health Sciences
Primary completion: Jan 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Number Meeting Success Criterion	10; 5; 0	>0.05

Summary

The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.

Eligibility Criteria

Inclusion Criteria

Patients with complex regional pain syndrome (CRPS), type I involving a lower extremity

Exclusion Criteria

Pregnancy
Allergy to clonidine
Currently taking clonidine or other direct a2-adrenergic agonists, or taking cholinesterase inhibitors
Patients with any serious or unstable medical problems (heart, lung, liver, kidney, or nervous system disease)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00349921). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.